Le Lézard
Classified in: Health
Subjects: DIS, FVT

Global Down Syndrome Foundation Thanks Congressional Leaders for Scheduling Hearing on the Importance of Down Syndrome Research and its Potential for Discoveries Across Major Diseases


WASHINGTON, Oct. 18, 2017 /PRNewswire/ -- The Global Down Syndrome Foundation thanked Chairman Tom Cole (R-OK) and Ranking Member Rosa DeLauro (D-CT) for scheduling a hearing on Down syndrome research with the U.S. House of Representatives Appropriations Subcommittee on Labor, Health and Human Services, and Education. The hearing will take place on Wednesday, October 25, 2017. Titled "Down Syndrome: Update on the State of the Science & Potential for Discoveries Across Other Major Diseases," the hearing will be the first Congressional hearing to explore how Down syndrome research can lead to new treatments for life-altering medical conditions including Alzheimer's disease, autoimmune disorders, and cancer. The hearing will include testimony from Rep. Cathy McMorris Rodgers (R-WA),  Rep. Cheri Bustos (D-IL), and Rep. Pete Sessions (R-TX), all champions for Down syndrome research funding in Congress.

"Funding for Down syndrome research at the National Institutes of Health unquestionably affects the health of people with Down syndrome," said Global Down Syndrome Foundation President & CEO Michelle Sie Whitten. "This important hearing will explore how current and future Down syndrome research can help people with Down syndrome and lead to life-changing treatments for devastating diseases like Alzheimer's and cancer. We are grateful to Chairman Tom Cole and Ranking Member Rosa DeLauro for scheduling this important hearing so Congress can learn more about the broad impact of Down syndrome research for millions of people who live with this particular condition, and for countless others who can benefit from the groundbreaking medical treatments that will develop as a result."

"The advocacy efforts of Rep. Cathy McMorris Rodgers, Rep. Cheri Bustos, and Rep. Pete Sessions have been instrumental in advancing Down syndrome research," Whitten continued. "Their testimony will underscore the need to increase funding so we can continue these important efforts for people with Down syndrome and their families."

The Subcommittee will also hear testimony from internationally recognized researchers and leaders from the Down syndrome community including:

Michelle Sie Whitten, Founder, CEO, and President of the Global Down Syndrome Foundation

Dr. Joaquín M. Espinosa, Executive Director of the Linda Crnic Institute for Down Syndrome and Director of The Functional Genomics Facility, University of Colorado School of Medicine, and Co-Leader of the Molecular Oncology Program at the University of Colorado Cancer Center

Dr. William Mobley, Executive Director of the Down Syndrome Center for Research and Treatment, and Florence Riford Chair of Alzheimer's Disease Research, University of California - San Diego

Frank Stephens
Actor, Author and Advocate, Board of Directors of Special Olympics Virginia

Additional information can be found on the House Committee on Appropriation web site.

Read more about the Global Down Syndrome Foundation here: https://www.globaldownsyndrome.org/

Media Contact
Name: Ed Mullen
Email: [email protected]
Phone: (202) 329-4855

Anca Call
Email: [email protected]
Phone: (720) 320-3832

Kathy Green
Email: [email protected]

Follow on Twitter at: https://twitter.com/GDSFoundation
Follow on Facebook at: https://www.facebook.com/GDSFoundation/

SOURCE Global Down Syndrome Foundation

Related Links

https://www.globaldownsyndrome.org/ 

https://appropriations.house.gov/calendar/eventsingle.aspx?EventID=395058

SOURCE Global Down Syndrome Foundation


These press releases may also interest you

at 16:45
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered...

at 16:30
Today, the Biden-Harris Administration released a final rule under Section 1557, the core nondiscrimination provision of the Affordable Care Act. This groundbreaking rule marks a critical step in protecting access to health care and coverage for...

at 16:14
eNeura, a pioneering leader in therapeutic solutions, proudly announces a monumental milestone in its journey towards revolutionizing migraine treatment. With unwavering commitment to innovation and patient well-being, eNeura has already reached...

at 16:10
bluebird bio, Inc. today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December...

at 16:10
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual...

at 16:00
This program will support individuals in Putnam County with Opioid Use Disorder and co-occurring substance use and mental health conditions through peer support and harm reduction for the broader Putnam County community. A...



News published on and distributed by: